Related Experiment Video

Updated: Aug 25, 2026

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer

Toshiro Shirakawa1, Akinobu Gotoh, Zhujun Zhang

  • 1International Center for Medical Research, Kobe University School of Medicine, Kobe, Japan.

Urology
|March 19, 2004
PubMed
Abstract

Insights

This study developed a novel gene therapy for testicular cancer using the human chorionic gonadotropin-beta (hCG-beta) promoter. The hCG-beta promoter selectively targeted and inhibited tumor growth in preclinical models, offering a promising new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Testicular cancer relapse after chemotherapy presents a clinical challenge.
  • Serum human chorionic gonadotropin-beta (hCG-beta) is a key tumor marker in testicular cancer.
  • hCG-beta levels predict treatment outcomes, indicating its potential as a therapeutic target.

Purpose of the Study:

  • To develop a targeted gene therapy for testicular cancer using the hCG-beta promoter.
  • To investigate the tissue-specific activity of the hCG-beta promoter for selective cancer cell killing.
  • To assess the efficacy of a novel gene therapy agent in preclinical models.

Main Methods:

  • Utilized human testicular (NEC 8), prostate (PC-3), and bladder (WH) cancer cell lines.
  • Analyzed hCG-beta promoter activity using transient expression experiments.
  • Generated a recombinant adenovirus (Ad-hCG-beta-TK) and tested its tissue-specific activity in vitro and in vivo.

Main Results:

  • The hCG-beta promoter showed significantly higher activity in hCG-beta-producing NEC 8 cells compared to PC-3 and WH cells.
  • In vitro, Ad-hCG-beta-TK with acyclovir selectively inhibited NEC 8 cell growth.
  • In vivo, Ad-hCG-beta-TK with acyclovir significantly suppressed subcutaneous NEC 8 tumor growth in nude mice.

Conclusions:

  • The study demonstrates the potential of tissue-specific hCG-beta promoters for targeted testicular germ cell tumor therapy.
  • This approach offers a strategy to selectively kill cancer cells, minimizing damage to healthy tissues.
  • Further development of this gene therapy could provide a new treatment option for relapsed testicular cancer.

More Related Videos

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.